DDInter542 DDInter1492
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Dicoumarol {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Dicoumarol {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Dicoumarol {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is regulated by {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ponatinib
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Ponatinib
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) STAMBP
STAMBP {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Dicoumarol {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is regulated by {v} (Gene) IL1B
IL1B {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Dicoumarol {u} (Compound) binds {v} (Gene) GPR35
GPR35 {u} (Gene) regulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Dicoumarol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Ponatinib (Compound)
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Ponatinib
Dicoumarol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Ponatinib
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Dicoumarol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is regulated by RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with STAMBP (Gene) and STAMBP (Gene) is downregulated by Ponatinib (Compound)
Dicoumarol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is regulated by IL1B (Gene) and IL1B (Gene) is upregulated by Ponatinib (Compound)
Dicoumarol (Compound) binds GPR35 (Gene) and GPR35 (Gene) regulates DLD (Gene) and DLD (Gene) is downregulated by Ponatinib (Compound)